Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | PGR | P06401 | 2/20 | 0.71 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.71 |
| ▸ | SHBG | P04278 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | AR | P10275 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8538851 | 0.91 | HIF1A (0.69) | HIF1ALMNANR3C1SMN1; SMN2CYP2C19 | |
| SCHEMBL603002 | 0.91 | HIF1A (0.69) | HIF1ALMNANR3C1SMN1; SMN2CYP2C19 | |
| SCHEMBL10730817 | 0.91 | HIF1A (0.68) | HIF1ALMNANR3C1SMN1; SMN2CYP2C19 | |
| SCHEMBL3638583 | 0.91 | HIF1A (0.68) | HIF1ALMNANR3C1SMN1; SMN2CYP2C19 | |
| SCHEMBL11814284 | 0.90 | HIF1A (0.81) | HIF1ALMNANR3C1SMN1; SMN2CYP2C19 | |
| SCHEMBL606810 | 0.90 | HIF1A (0.67) | HIF1ALMNANR3C1SMN1; SMN2CYP2C19 | |
| SCHEMBL606477 | 0.89 | HIF1A (0.66) | HIF1ALMNANR3C1SMN1; SMN2CYP2C19 | |
| SCHEMBL9437393 | 0.88 | HIF1A (0.75) | HIF1ALMNANR3C1SMN1; SMN2CYP2C19 | |
| SCHEMBL16020569 | 0.88 | HIF1A (0.78) | HIF1ALMNANR3C1SMN1; SMN2CYP2C19 | |
| SCHEMBL3108473 | 0.88 | HIF1A (0.69) | HIF1ALMNANR3C1SMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106572970-B | Novel gel for topical administration of non-steroidal anti-inflammatory drugs for relief of musculoskeletal pain and method of making same | 詹姆斯·布兰查德 | 2021-04-06 | — | — | CN | claimed |
| CN-106632561-A | Method for preparing difluprednate | 广州仁恒医药科技股份有限公司 | 2017-05-10 | — | — | CN | claimed |
| WO-2015191402-A1 | NOVEL GEL FOR TOPICAL DELIVERY OF NSAIDS TO PROVIDE RELIEF OF MUSCULOSKELETAL PAIN AND METHODS FOR ITS PREPARATION | BLANCHARD JAMES (US) | 2015-12-17 | — | — | WO | claimed |
| US-9012402-B1 | Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation | BLANCHARD JAMES (US) | 2015-04-21 | — | — | US | claimed |
| US-20090075328-A1 | PROCESS FOR THE OVEREXPRESSION OF DEHYDROGENASES | SPELLIG TILMAN | 2009-03-19 | — | — | US | claimed |
| US-7416866-B2 | Process for the overexpression of dehydrogenases | SCHERING AG (DE) | 2008-08-26 | — | — | US | claimed |
| CN-101132766-A | Tablet containing steroid hormone | LOHMANN THERAPIE SYST LTS (DE) | 2008-02-27 | — | — | CN | claimed |
| EP-0374185-B1 | IMPROVED 9$g(a)-DEHALOGENATION PROCESS | THE UPJOHN COMPANY (US) | 1993-02-10 | — | — | EP | claimed |
| US-4252796-A | ALUMINUM COMPOUNDS, ANTIINFLAMMATORY AGENTS | YU RUEY J | 1981-02-24 | — | — | US | claimed |
| US-4246261-A | HYDROXY ACIDS, ESTERS, LACTONES | SCOTT EUGENE J VAN | 1981-01-20 | — | — | US | claimed |
| US-3956349-A | TRIETHYL ORTHOACETATE, ACID CATALYST | SYNTEX (U.S.A.) INC. (US) | 1976-05-11 | — | — | US | claimed |
| US-12636296-B1 | Cannabinol analogs and their use as pharmacologically active agents | NALU BIO, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| CN-119306782-B | Glucocorticoid Process for the preparation of compounds | 中国农业大学 | 2026-05-12 | — | — | CN | disclosed |
| US-12605332-B2 | Transdermal delivery formulations | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2026-04-21 | — | — | US | disclosed |
| US-12583832-B2 | Cannabinoid analogs, formulations, and methods of use | NALU BIO, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-4339390-A | Preferential immunoreactivity of syn-isomer of cortisol derivative | ABBOTT LABORATORIES (US) | 1982-07-13 | — | — | US | disclosed |
| US-4316902-A | Therapeutic compositions and vehicles for topical pharmaceuticals | YU RUEY J | 1982-02-23 | — | — | US | disclosed |
| US-4252796-A | ALUMINUM COMPOUNDS, ANTIINFLAMMATORY AGENTS | YU RUEY J | 1981-02-24 | — | — | US | disclosed |
| US-4246261-A | HYDROXY ACIDS, ESTERS, LACTONES | SCOTT EUGENE J VAN | 1981-01-20 | — | — | US | disclosed |
| US-3956349-A | TRIETHYL ORTHOACETATE, ACID CATALYST | SYNTEX (U.S.A.) INC. (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636296-B1 | Cannabinol analogs and their use as pharmacologically active agents | CNR1, CNR2, OPRL1 | HIF1A 894/4885LMNA 750/4885NR3C1 43/4885 |
| US-12605332-B2 | Transdermal delivery formulations | NOS1, NOS2, VDR | HIF1A 685/4885LMNA 3142/4885NR3C1 479/4885 |
| US-12583832-B2 | Cannabinoid analogs, formulations, and methods of use | CNR1, CNR2, CYP8B1 | HIF1A 2161/4885LMNA 2505/4885NR3C1 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.